Skip to content

Sigilon Therapeutics, Inc.

CIK 0001821323

← back to feed
Revenue (TTM)
$17.89M
+34.8% YoY Q2 Aug 2023
Net Income (TTM)
−$37.9M
+43.7% YoY Q2 Aug 2023
EPS Diluted (TTM)
−$9.26
+44.9% YoY Q2 Aug 2023
Gross Margin
—
Q2 Aug 2023
Operating Margin
-207.6%
Q2 Aug 2023
Net Margin
-211.8%
Q2 Aug 2023
Free Cash Flow (TTM)
−$69.99M
Q2 Aug 2023
Cash
$19.62M
Q2 Aug 2023
Total Debt
$17.08M
Q2 Aug 2023
Shares Outstanding
2.51M sh
Q2 Aug 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings